Integrated Report

Overview

The report presents Kobayashi Pharmaceutical's FY2020 performance amid COVID-19, including ¥150.5 billion in net sales and a 17.2% operating income margin. It highlights a Group target to reduce Scope 1 and 2 CO2 emissions 54.6% from 2017 levels by 2030. The ESG program includes a dedicated ESG department, material-issue prioritization, and CDP climate and water scores of C and B, respectively. The consolidated workforce was 3,473 employees at year-end.

Document

Report type: Integrated Report
Class: Embedded
Scope: Full report
Fiscal year: 2020
Period: 1 January 2020 – 31 December 2020
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Ratings

CDP score

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services